Skip to main content

Advertisement

SpringerLink
Log in

Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome

  • Case Report
  • Published:
Modern Rheumatology

Abstract

We report a 57-year-old female case of intractable adult-onset Still’s disease (AOSD). Initial high-dose prednisolone therapy was ineffective, and macrophage-activation syndrome (MAS) manifested after one session of additional tocilizumab therapy. After successful treatment for MAS with lipo-dexamethasone and cyclosporin, tocilizumab therapy aided in the rapid reduction of the therapeutic steroid dose. Tocilizumab may be useful for maintenance therapy for AOSD, although its efficacy is unclear for the highly active phase of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Pay S, Türkçapar N, Kalyoncu M, Simşek I, Beyan E, Ertenli I, Oztürk MA, Düzgün N, Erdem H, Ozbalkan Z, Kiraz S, Kinikli G, Besbas N, Dinç A, Ateş A, Olmez U, Calgüneri M, Aydintuğ OT, Bakkaloğlu A, Turan M, Turgay M, Karaaslan Y, Topaloğlu R, Duman M, Ozen S. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25:639–44.

    Article  PubMed  Google Scholar 

  2. Bywaters EG. Still’s disease in the adult. Ann Rheum Dis. 1971;30:121–33.

    Article  CAS  PubMed  Google Scholar 

  3. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–30.

    CAS  PubMed  Google Scholar 

  4. Efthimiou P, Georgy S. Pathogenesis and management of adult-onset Still’s disease. Semin Arthritis Rheum. 2006;36:144–52.

    Article  CAS  PubMed  Google Scholar 

  5. Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. 2005;52:1794–803.

    Article  CAS  PubMed  Google Scholar 

  6. Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs. 2009;69:609–32.

    Article  CAS  PubMed  Google Scholar 

  7. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817–29.

    Article  CAS  PubMed  Google Scholar 

  8. Ohsugi Y. Recent advances in immunopathophysiology of tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull. 2007;30:2001–6.

    Article  CAS  PubMed  Google Scholar 

  9. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI). Mod Rheumatol. 2009;19:12–9.

    Article  CAS  PubMed  Google Scholar 

  10. Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2005;28:231–8.

    Article  CAS  PubMed  Google Scholar 

  11. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818–25.

    Article  CAS  PubMed  Google Scholar 

  12. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.

    Google Scholar 

  13. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with RA and Castleman. Blood. 2008;112:3959–64.

    Article  CAS  PubMed  Google Scholar 

  14. Nakamura H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N. A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol. 2009;19:69–72.

    Article  Google Scholar 

  15. Matsumoto K, Nagashima T, Takatori S, Kawahara Y, Yagi M, Iwamoto M, Okazaki H, Minota S. Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab. Clin Rheumatol. 2009;28:485–7.

    Article  PubMed  Google Scholar 

  16. De Bandt M, Saint-Marcoux B. TCZ for multirefractory AOSD. Ann Rheum Dis. 2009;68:153–4.

    Article  PubMed  Google Scholar 

  17. Behrens EM. MAS in rheumatic disease. What is the role of the antigen presenting cell? Autoimmun Rev. 2008;7:305–8.

    Google Scholar 

  18. Szyper-Kravitz M. The hemophagocytic syndrome/macrophage activation syndrome: a final common pathway of a cytokine storm. Isr Med Assoc J. 2009;11:633–4.

    PubMed  Google Scholar 

  19. Zhang X, Mosser DM. Macrophage activation by endogenous danger signals. J Pathol. 2008;214:161–78.

    Article  CAS  PubMed  Google Scholar 

  20. Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, Dupond JL, Larroche C, Piette AM, Mechenstock D, Ziza JM, Arlaud J, Labussiere AS, Desvaux A, Baty V, Blanche P, Schaeffer A, Piette JC, Guillevin L, Boissonnas A, Christoforov B. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 2003;49:633–9.

    Google Scholar 

  21. Arlet JB, Le TH, Marinho A, Amoura Z, Wechsler B, Papo T, Piette JC. Reactive haemophagocytic syndrome in adult-onset Still’s disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006;65:1596–601.

    Article  PubMed  Google Scholar 

  22. Hot A, Toh ML, Coppéré B, Perard L, Madoux MH, Mausservey C, Desmurs-Clavel H, Ffrench M, Ninet J. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients. Medicine (Baltimore). 2010;89:37–46.

    Article  Google Scholar 

  23. Amenomori M, Migita K, Miyashita T, Yoshida S, Ito M, Eguchi K, Ezaki H. Cytomegalovirus-associated hemophagocytic syndrome in a patient with adult onset Still’s disease. Clin Exp Rheumatol. 2005;23:100–2.

    CAS  PubMed  Google Scholar 

  24. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85:421–6.

    Article  CAS  PubMed  Google Scholar 

  25. Stéphan JL, Koné-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology. 2001;40:1285–92.

    Article  PubMed  Google Scholar 

  26. Mitamura M, Tada Y, Koarada S, Inoue H, Suematsu R, Ohta A, Nagasawa K. Cyclosporin A treatment for Japanese patients with severe adult-onset Still’s disease. Mod Rheumatol. 2009;19:57–63.

    Article  CAS  PubMed  Google Scholar 

  27. Fautrel B, Borget C, Rozenberg S, Meyer O, Le Loët X, Masson C, Koeger AC, Kahn MF, Bourgeois P. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still’s disease. J Rheumatol. 1999;26:373–8.

    CAS  PubMed  Google Scholar 

  28. Beresford MW, Baildam EM. New advances in the management of juvenile idiopathic arthritis. 2: The era of biologicals. Arch Dis Child Educ Pract Ed. 2009;94:151–6.

    Google Scholar 

  29. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis. 2008;67:1145–52.

    Article  CAS  PubMed  Google Scholar 

  30. Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch National Register. Ann Rheum Dis. 2009;68:635–41.

    Google Scholar 

  31. Pain CE, McCann LJ. Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics. 2009;3:127–39.

    CAS  PubMed  Google Scholar 

  32. Babacan T, Onat AM, Pehlivan Y, Comez G, Karakök M. Successful treatment of refractory adult Still’s disease and membranous glomerulonephritis with infliximab. Clin Rheumatol. 2010;29:423–6.

    Article  PubMed  Google Scholar 

  33. Gianella S, Schaer DJ, Schwarz U, Kurrer M, Heppner FL, Fehr J, Seebach JD. Retinal microangiopathy and rapidly fatal cerebral edema in a patient with adult-onset Still’s disease and concurrent macrophage activation syndrome. Am J Hematol. 2008;83:424–7.

    Article  PubMed  Google Scholar 

  34. Stern A, Riley R, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still’s disease after initiation of etanercept therapy. J Clin Rheumatol. 2001;7:252–6.

    Article  CAS  PubMed  Google Scholar 

  35. Cortis E, Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl. 2006;95:38–41.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Rheumatic Diseases, National Center of Global Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan

    Masafumi Kobayashi, Yuko Takahashi, Hiroyuki Yamashita, Hiroshi Kaneko & Akio Mimori

Authors
  1. Masafumi Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuko Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroyuki Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroshi Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akio Mimori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuko Takahashi.

About this article

Cite this article

Kobayashi, M., Takahashi, Y., Yamashita, H. et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome. Mod Rheumatol 21, 92–96 (2011). https://doi.org/10.1007/s10165-010-0348-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-010-0348-9

Keywords

Search

Navigation